Parkinson’s disease (PD) is a common neurodegenerative disorder arising from an interplay between genetic and environmental risk factors. Studies have suggested that the pathological hallmarks of intraneuronal α-synuclein aggregations may start from the olfactory bulb and the enteric nervous system of the gut and later propagate to the brain via the olfactory tract and the vagus nerve. This hypothesis correlates well with clinical symptoms, such as constipation, that may develop up to 20 years before the onset of PD motor symptoms. Recent interest in the gut–brain axis has led to vigorous research into the gastrointestinal pathology and gut microbiota changes in patients with PD. In this review, we provide current clinical and pathological evidence of gut involvement in PD by summarizing the changes in gut microbiota composition and gut inflammation associated with its pathogenesis.
Citations
Citations to this article as recorded by
Buty and the beast: the complex role of butyrate in Parkinson’s disease Joshua D. Elford, Nanette Becht, Johan Garssen, Aletta D. Kraneveld, Paula Perez-Pardo Frontiers in Pharmacology.2024;[Epub] CrossRef
Acupuncture ameliorates depression-like behavior of poststroke depression model rats through the regulation of gut microbiota and NLRP3 inflammasome in the colon Wa Cai, Xi-Fang Wei, Jing-Ruo Zhang, Larissa Tao, Dong Li, Kun Zhang, Wei-Dong Shen NeuroReport.2024;[Epub] CrossRef
Intestinal Barrier Function and Neurodegenerative Disease Shijing Wu, Liangfang Yang, Yiwei Fu, Zhimin Liao, De Cai, Zhou Liu CNS & Neurological Disorders - Drug Targets.2024; 23(9): 1134. CrossRef
The Role of the Gut Microbiota in Sanfilippo Syndrome’s Physiopathology: An Approach in Two Affected Siblings Raquel Barbero-Herranz, María Garriga-García, Ana Moreno-Blanco, Esther Palacios, Pedro Ruiz-Sala, Saioa Vicente-Santamaría, Sinziana Stanescu, Amaya Belanger-Quintana, Guillem Pintos-Morell, Beatriz Arconada, Rosa del Campo, José Avendaño-Ortiz International Journal of Molecular Sciences.2024; 25(16): 8856. CrossRef
Adipose tissue, systematic inflammation, and neurodegenerative diseases AnaPaula de A. Boleti, PedroHenrique de O. Cardoso, BrenoEmanuel F. Frihling, PatríciaSouza e Silva, LuizFilipe R. N. de Moraes, Ludovico Migliolo Neural Regeneration Research.2023; 18(1): 38. CrossRef
Parkinson's Disease: A Multisystem Disorder Helena Nunes Costa, Ana Raquel Esteves, Nuno Empadinhas, Sandra Morais Cardoso Neuroscience Bulletin.2023; 39(1): 113. CrossRef
Brain modulation by the gut microbiota: From disease to therapy Sarmistha Mitra, Raju Dash, Amena Al Nishan, Sarmin Ummey Habiba, Il Soo Moon Journal of Advanced Research.2023; 53: 153. CrossRef
Plasma Metabolic Analysis Reveals the Dysregulation of Short-Chain Fatty Acid Metabolism in Parkinson’s Disease Ao Qi, Lulu Liu, Junjie Zhang, Simei Chen, Simin Xu, Yusen Chen, Lijiang Zhang, Chun Cai Molecular Neurobiology.2023; 60(5): 2619. CrossRef
Fecal microbiota transplantation in Parkinson's disease—A randomized repeat-dose, placebo-controlled clinical pilot study Herbert L. DuPont, Jessika Suescun, Zhi-Dong Jiang, Eric L. Brown, Heather T. Essigmann, Ashley S. Alexander, Andrew W. DuPont, Tehseen Iqbal, Netanya S. Utay, Michael Newmark, Mya C. Schiess Frontiers in Neurology.2023;[Epub] CrossRef
Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases Mohamed S. Attia, Ahmed Yahya, Nada Abdel Monaem, Shereen A. Sabry Saudi Pharmaceutical Journal.2023; 31(3): 417. CrossRef
GSDMD in peripheral myeloid cells regulates microglial immune training and neuroinflammation in Parkinson's disease Bingwei Wang, Yan Ma, Sheng Li, Hang Yao, Mingna Gu, Ying Liu, You Xue, Jianhua Ding, Chunmei Ma, Shuo Yang, Gang Hu Acta Pharmaceutica Sinica B.2023; 13(6): 2663. CrossRef
Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson’s disease Júlio César Claudino dos Santos, Leandro Freitas Oliveira, Felipe Micelli Noleto, Camilla Teixeira Pinheiro Gusmão, Gerly Anne de Castro Brito, Glauce Socorro de Barros Viana Neural Regeneration Research.2023; 18(12): 2611. CrossRef
Beyond the Microbiota: Understanding the Role of the Enteric Nervous System in Parkinson’s Disease from Mice to Human Martina Montanari, Paola Imbriani, Paola Bonsi, Giuseppina Martella, Antonella Peppe Biomedicines.2023; 11(6): 1560. CrossRef
Effects of gut microbiota on neurodegenerative diseases Saima Khatoon, Nida Kalam, Summya Rashid, Gulnaz Bano Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes Frances Widjaja, Ivonne M. C. M. Rietjens Biomedicines.2023; 11(10): 2658. CrossRef
Association between the risk and severity of Parkinson’s disease and plasma homocysteine, vitamin B12 and folate levels: a systematic review and meta-analysis Yuxin Quan, Jisen Xu, Qing Xu, Zhiqing Guo, Ruwei Ou, Huifang Shang, Qianqian Wei Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson’s disease Ehraz Anis, Aoji Xie, Lena Brundin, Patrik Brundin Trends in Endocrinology & Metabolism.2022; 33(2): 147. CrossRef
Animal models of brain-first and body-first Parkinson's disease Nathalie Van Den Berge, Ayse Ulusoy Neurobiology of Disease.2022; 163: 105599. CrossRef
Microbiome Changes in Humans with Parkinson’s Disease after Photobiomodulation Therapy: A Retrospective Study Brian Bicknell, Ann Liebert, Craig S. McLachlan, Hosen Kiat Journal of Personalized Medicine.2022; 12(1): 49. CrossRef
Passive Immunization in Alpha-Synuclein Preclinical Animal Models Jonas Folke, Nelson Ferreira, Tomasz Brudek, Per Borghammer, Nathalie Van Den Berge Biomolecules.2022; 12(2): 168. CrossRef
Dietary Succinoglycan Riclin Improves Glycemia Control in Mice with Type 2 Diabetes Zhao Ding, Yang Zhao, Junhao Liu, Wenhao Ge, Xi Xu, Shiming Wang, Jianfa Zhang Journal of Agricultural and Food Chemistry.2022; 70(6): 1819. CrossRef
Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling Sevag Hamamah, Armin Aghazarian, Anthony Nazaryan, Andras Hajnal, Mihai Covasa Biomedicines.2022; 10(2): 436. CrossRef
Distribution of α-Synuclein Aggregation in the Peripheral Tissues Yan-yan Li, Tian-tian Zhou, Yi Zhang, Nai-Hong Chen, Yu-He Yuan Neurochemical Research.2022; 47(12): 3627. CrossRef
Effects of Subdiaphragmatic Vagotomy in the MPTP-induced Neurotoxicity in the Striatum and Colon of Mice Jiajing Shan, Youge Qu, Jiancheng Zhang, Li Ma, Kenji Hashimoto Clinical Psychopharmacology and Neuroscience.2022; 20(2): 389. CrossRef
Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies Mie Kristine Just, Hjalte Gram, Vasileios Theologidis, Poul Henning Jensen, K. Peter R. Nilsson, Mikael Lindgren, Karoline Knudsen, Per Borghammer, Nathalie Van Den Berge Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients María Romo-Vaquero, Emiliano Fernández-Villalba, Ana-Luisa Gil-Martinez, Lorena Cuenca-Bermejo, Juan Carlos Espín, María Trinidad Herrero, María Victoria Selma Food & Function.2022; 13(11): 6306. CrossRef
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease Hiroshi Nishiwaki, Mikako Ito, Tomonari Hamaguchi, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Takumi Yoshida, Hiroyuki Hanada, Ichiro Takeuchi, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno npj Parkinson's Disease.2022;[Epub] CrossRef
Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes Amnon A. Berger, Ariel Winnick, Jonathan Izygon, Binil M. Jacob, Jessica S. Kaye, Rachel J. Kaye, Elisa E. Neuchat, Adam M. Kaye, Edward S. Alpaugh, Elyse M. Cornett, Andrew H. Han, Alan D. Kaye Health Psychology Research.2022;[Epub] CrossRef
The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases George Tsafaras, Veerle Baekelandt Neurobiology of Disease.2022; 172: 105806. CrossRef
What Is the Prognostic Significance of Rapid Eye Movement Sleep Without Atonia in a Polysomnogram? Frank Ralls, Lisa Cutchen, Madeleine M. Grigg-Damberger Journal of Clinical Neurophysiology.2022; 39(5): 346. CrossRef
Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism Jose Ivo A. Beserra-Filho, Amanda Maria-Macêdo, Suellen Silva-Martins, Ana Cláudia Custódio-Silva, Beatriz Soares-Silva, Sara Pereira Silva, Rafael Herling Lambertucci, Adriano Antunes de Souza Araújo, Angélica Maria Lucchese, Lucindo J. Quintans-Júnior, Metabolic Brain Disease.2022; 37(7): 2331. CrossRef
Oral and gut dysbiosis leads to functional alterations in Parkinson’s disease Sungyang Jo, Woorim Kang, Yun Su Hwang, Seung Hyun Lee, Kye Won Park, Mi Sun Kim, Hyunna Lee, Hyung Jeong Yoon, Yoo Kyoung Park, Mauricio Chalita, Je Hee Lee, Hojun Sung, Jae-Yun Lee, Jin-Woo Bae, Sun Ju Chung npj Parkinson's Disease.2022;[Epub] CrossRef
Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson’s Disease Ritu Soni, Jigna Shah ACS Chemical Neuroscience.2022; 13(15): 2240. CrossRef
Therapeutic potential of short-chain fatty acid production by gut microbiota in neurodegenerative disorders Sarika Yadav, Ashish Dwivedi, Anurag Tripathi, Amit Kumar Tripathi Nutrition Research.2022; 106: 72. CrossRef
Development of neurodegenerative disorders and the role of gut Woong-Woo Lee Journal of Geriatric Neurology.2022; 1(2): 53. CrossRef
What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review Bruno Bonnechère, Najaf Amin, Cornelia van Duijn International Journal of Molecular Sciences.2022; 23(22): 13665. CrossRef
Gut microbiota in dementia with Lewy bodies Hiroshi Nishiwaki, Jun Ueyama, Kenichi Kashihara, Mikako Ito, Tomonari Hamaguchi, Tetsuya Maeda, Yoshio Tsuboi, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno npj Parkinson's Disease.2022;[Epub] CrossRef
Gut dysbiosis in stroke and its implications on Alzheimer’s disease‐like cognitive dysfunction Justin Cho, You Jeong Park, Bella Gonzales‐Portillo, Madeline Saft, Blaise Cozene, Nadia Sadanandan, Cesar V. Borlongan CNS Neuroscience & Therapeutics.2021; 27(5): 505. CrossRef
Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson’s Disease Szu-Ju Chen, Yu-Chiao Chi, Chang-Han Ho, Wei-Shiung Yang, Chin-Hsien Lin Journal of Parkinson's Disease.2021; 11(3): 1129. CrossRef
Parkinson's disease and the gut: Models of an emerging relationship Adam J. Bindas, Subhash Kulkarni, Ryan A. Koppes, Abigail N. Koppes Acta Biomaterialia.2021; 132: 325. CrossRef
Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats Nathalie Van Den Berge, Nelson Ferreira, Trine Werenberg Mikkelsen, Aage Kristian Olsen Alstrup, Gültekin Tamgüney, Páll Karlsson, Astrid Juhl Terkelsen, Jens Randel Nyengaard, Poul Henning Jensen, Per Borghammer Brain.2021; 144(6): 1853. CrossRef
Desulfovibrio Bacteria Are Associated With Parkinson’s Disease Kari E. Murros, Vy A. Huynh, Timo M. Takala, Per E. J. Saris Frontiers in Cellular and Infection Microbiology.2021;[Epub] CrossRef
“Janus-Faced” α-Synuclein: Role in Parkinson’s Disease Bipul Ray, Arehally M. Mahalakshmi, Sunanda Tuladhar, Abid Bhat, Asha Srinivasan, Christophe Pellegrino, Anbarasu Kannan, Srinivasa Rao Bolla, Saravana Babu Chidambaram, Meena Kishore Sakharkar Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease Jonas Ghyselinck, Lynn Verstrepen, Frédéric Moens, Pieter Van Den Abbeele, Arnout Bruggeman, Jawal Said, Barry Smith, Lynne Ann Barker, Caroline Jordan, Valentina Leta, K. Ray Chaudhuri, Abdul W. Basit, Simon Gaisford International Journal of Pharmaceutics: X.2021; 3: 100087. CrossRef
The Role of The Gut Microbiome in Parkinson’s Disease Amy Gallop, James Weagley, Saif-ur-Rahman Paracha, George Grossberg Journal of Geriatric Psychiatry and Neurology.2021; 34(4): 253. CrossRef
The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’s Disease Gianfranco Natale, Larisa Ryskalin, Gabriele Morucci, Gloria Lazzeri, Alessandro Frati, Francesco Fornai Life.2021; 11(8): 732. CrossRef
Regulation of neurotoxicity in the striatum and colon of MPTP-induced Parkinson’s disease mice by gut microbiome Jiajing Shan, Youge Qu, Siming Wang, Yan Wei, Lijia Chang, Li Ma, Kenji Hashimoto Brain Research Bulletin.2021; 177: 103. CrossRef
Cholecystectomy and subsequent risk of Parkinson’s disease: a nationwide retrospective cohort study Ryul Kim, Jee-Young Lee, Sanghyun Park, Kyungdo Han, Cheol Min Shin npj Parkinson's Disease.2021;[Epub] CrossRef
Benefits of Helicobacter pylori Eradication on Extragastric Diseases Tae Jun Kim, Hyuk Lee The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(4): 275. CrossRef
Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson’s disease Bartłomiej Sankowski, Karolina Księżarczyk, Emilia Raćkowska, Stanisław Szlufik, Dariusz Koziorowski, Joanna Giebułtowicz Clinica Chimica Acta.2020; 501: 165. CrossRef
The microbiome-gut-brain axis in acute and chronic brain diseases Corinne Benakis, Camille Martin-Gallausiaux, Jean-Pierre Trezzi, Philip Melton, Arthur Liesz, Paul Wilmes Current Opinion in Neurobiology.2020; 61: 1. CrossRef
The progress of gut microbiome research related to brain disorders Sibo Zhu, Yanfeng Jiang, Kelin Xu, Mei Cui, Weimin Ye, Genming Zhao, Li Jin, Xingdong Chen Journal of Neuroinflammation.2020;[Epub] CrossRef
Minireview on the Relations between Gut Microflora and Parkinson’s Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities Ovidiu-Dumitru Ilie, Alin Ciobica, Jack McKenna, Bogdan Doroftei, Ioannis Mavroudis, Tuane B. Sampaio Oxidative Medicine and Cellular Longevity.2020; 2020: 1. CrossRef
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? Carolina Pellegrini, Luca Antonioli, Vincenzo Calderone, Rocchina Colucci, Matteo Fornai, Corrado Blandizzi Progress in Neurobiology.2020; 191: 101806. CrossRef
Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease Hiroshi Nishiwaki, Mikako Ito, Tomohiro Ishida, Tomonari Hamaguchi, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Teppei Shimamura, Hiroshi Mori, Ken Kurokawa, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno Movement Disorders.2020; 35(9): 1626. CrossRef
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons Maria Fouka, Panagiota Mavroeidi, Grigoria Tsaka, Maria Xilouri Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Role of Carbon Monoxide in Host–Gut Microbiome Communication Christopher P. Hopper, Ladie Kimberly De La Cruz, Kristin V. Lyles, Lauren K. Wareham, Jack A. Gilbert, Zehava Eichenbaum, Marcin Magierowski, Robert K. Poole, Jakob Wollborn, Binghe Wang Chemical Reviews.2020; 120(24): 13273. CrossRef
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease Chrysoula Marogianni, Maria Sokratous, Efthimios Dardiotis, Georgios M. Hadjigeorgiou, Dimitrios Bogdanos, Georgia Xiromerisiou International Journal of Molecular Sciences.2020; 21(22): 8421. CrossRef
Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson’s Disease Tennekoon B. Karunaratne, Chijioke Okereke, Marissa Seamon, Sharad Purohit, Chandramohan Wakade, Amol Sharma Nutrients.2020; 13(1): 28. CrossRef
Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson’s Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder Hiroshi Nishiwaki, Tomonari Hamaguchi, Mikako Ito, Tomohiro Ishida, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Teppei Shimamura, Hiroshi Mori, Ken Kurokawa, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno, Chaysavanh Manichanh mSystems.2020;[Epub] CrossRef
The Intestinal Barrier in Parkinson’s Disease: Current State of Knowledge Sven C. D. van IJzendoorn, Pascal Derkinderen, Teus van Laar Journal of Parkinson's Disease.2019; 9(s2): S323. CrossRef
Medical management, prevention and mitigation of environmental risks factors in Neurology J. Reis, G.C. Román, M. Giroud, V.S. Palmer, P.S. Spencer Revue Neurologique.2019; 175(10): 698. CrossRef
Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain Yaoyu Pu, Lijia Chang, Youge Qu, Siming Wang, Kai Zhang, Kenji Hashimoto Aging.2019; 11(17): 6915. CrossRef
Objective Recent reports of hearing impairment in Parkinson’s disease (PD) have suggested that auditory dysfunction could be a non-motor manifestation of PD. These reports were based on observations of elderly patients for whom presbycusis may, to some extent, have contributed to hearing dysfunction. Therefore, we aimed to explore the auditory functions in younger patients with PD. Methods We conducted a case-control study in a relatively younger (< 55 years of age at study time) population of PD patients and healthy volunteers to test whether auditory dysfunction is a significant non-motor dysfunction in PD. Pure tone audiometry (PTA) and brainstem evoked response audiometry (BERA) were performed in all participants. Results None of the patients or controls reported hearing deficits. Fifty-one patients with PD and 50 healthy volunteers who were age- and gender-matched to the patients participated. PTA-detected hearing impairment was found in 64.7% of patients and 28% of controls (p < 0.001) for both low-mid and/or high frequencies. Hearing impairment was more frequent in the younger subgroups of patients than age-matched controls, while the frequency of hearing impairment was similar in older groups of subjects. BERA was not different between patients and controls. Conclusion Asymptomatic auditory dysfunction is a common non-motor manifestation of early-onset PD and more frequent in younger patients, indicating that it may be independent of aging. The mechanism underlying this dysfunction appears to be peripheral, although a central dysfunction cannot be ruled out based on the findings of this study.
Citations
Citations to this article as recorded by
Hearing dysfunction heralds an increase in non-motor burden and a worse quality of life in Parkinson’s disease: new insights from non-motor spectrum Elena Garasto, Alessandro Stefani, Mariangela Pierantozzi, Matteo Conti, Arturo Moleti, Renata Sisto, Andrea Viziano, Claudio Liguori, Tommaso Schirinzi, Nicola Biagio Mercuri, Rocco Cerroni Neurological Sciences.2024; 45(9): 4299. CrossRef
Relationship of Hearing Loss to Parkinson’s Disease, Dementia, and APOE Genotype in Adults Chih-Hung Cha, Tsu-Kung Lin, Ching-Nung Wu, Chao-Hui Yang, Yi-Wen Huang, Chung-Feng Hwang Medicina.2024; 60(5): 703. CrossRef
Disturbance in the protein landscape of cochlear perilymph in an Alzheimer’s disease mouse model Masatoshi Fukuda, Hiroki Okanishi, Daisuke Ino, Kazuya Ono, Satoru Kawamura, Eri Wakai, Tsuyoshi Miyoshi, Takashi Sato, Yumi Ohta, Takashi Saito, Takaomi C. Saido, Hidenori Inohara, Yoshikatsu Kanai, Hiroshi Hibino, Abdelwahab Omri PLOS ONE.2024; 19(5): e0303375. CrossRef
Peripheral hearing in Parkinson’s disease: a systematic review Mariana S. Leme, Seisse G. G. Sanches, Renata M. M. Carvallo International Journal of Audiology.2023; 62(9): 805. CrossRef
(Zu-)Hören mit alterndem Gehirn – eine kognitive
Herausforderung Wilma Großmann Laryngo-Rhino-Otologie.2023; 102(S 01): S12. CrossRef
Is Hearing Loss a Risk Factor for Idiopathic Parkinson’s Disease? An English Longitudinal Study of Ageing Analysis Megan Rose Readman, Fang Wan, Ian Fairman, Sally A. Linkenauger, Trevor J. Crawford, Christopher J. Plack Brain Sciences.2023; 13(8): 1196. CrossRef
Hearing Loss and Disorders: The Repercussions of Climate Change Sue Sherratt American Journal of Audiology.2023; 32(4): 793. CrossRef
Association between hearing sensitivity and dopamine transporter availability in Parkinson’s disease Elena Garasto, Alessandro Stefani, Mariangela Pierantozzi, Rocco Cerroni, Matteo Conti, Simone Maranesi, Nicola B Mercuri, Agostino Chiaravalloti, Orazio Schillaci, Andrea Viziano, Arturo Moleti, Renata Sisto Brain Communications.2023;[Epub] CrossRef
Identifying Parkinson Risk Markers in Primary Care—Old Associations and New Insights Bhavana Patel, Shannon Chiu, Melissa J. Armstrong JAMA Neurology.2022; 79(4): 331. CrossRef
Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population Cristina Simonet, Jonathan Bestwick, Mark Jitlal, Sheena Waters, Aaron Ben-Joseph, Charles R. Marshall, Ruth Dobson, Soha Marrium, John Robson, Benjamin M. Jacobs, Daniel Belete, Andrew J. Lees, Gavin Giovannoni, Jack Cuzick, Anette Schrag, Alastair J. No JAMA Neurology.2022; 79(4): 359. CrossRef
Auditory impairment in H‐ABC tubulinopathy Alejandra Lopez‐Juarez, Arturo Gonzalez‐Vega, Anke Kleinert‐Altamirano, Valeria Piazza, Angeles Garduno‐Robles, Milvia Alata, Carlos Villaseñor‐Mora, Jose R. Eguibar, Carmen Cortes, Luis Carlos Padierna, Victor H. Hernandez Journal of Comparative Neurology.2021; 529(5): 957. CrossRef
The Effect of Parkinson's Disease on Otoacoustic Emissions and Efferent Suppression of Transient Evoked Otoacoustic Emissions Evelien De Groote, Annelies Bockstael, Dick Botteldooren, Patrick Santens, Miet De Letter Journal of Speech, Language, and Hearing Research.2021; 64(4): 1354. CrossRef
Hearing Loss in Neurological Disorders Siyu Li, Cheng Cheng, Ling Lu, Xiaofeng Ma, Xiaoli Zhang, Ao Li, Jie Chen, Xiaoyun Qian, Xia Gao Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Age-Related Changes in the Cochlea and Vestibule: Shared Patterns and Processes Vasiliki Paplou, Nick M. A. Schubert, Sonja J. Pyott Frontiers in Neuroscience.2021;[Epub] CrossRef
Auditory Dysfunction in Parkinson's Disease Zahra Jafari, Bryan E. Kolb, Majid H. Mohajerani Movement Disorders.2020; 35(4): 537. CrossRef
Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease Evelien De Groote, Kim De Keyser, Patrick Santens, Durk Talsma, Annelies Bockstael, Dick Botteldooren, Miet De Letter Frontiers in Neurology.2020;[Epub] CrossRef
Objective In Parkinson’s disease (PD), vitamin B12 levels are lower, and comorbid B12 deficiency has been associated with the development of neuropathy and early gait instability. Because little is known about B12 supplement use in PD, we sought to evaluate its use in a large PD cohort and, as an exploratory analysis, to determine whether baseline characteristics or disease progression differed according to B12 supplementation.
Methods We utilized data collected as part of the National Institutes of Health Exploratory Trials in PD (NET-PD) Long-term Study (LS-1), a longitudinal study of 1,741 participants. We stratified subjects into 4 groups according to daily supplement use: no B12, multivitamin (MVI) containing < 100 μg B12, B12 ≥ 100 μg, and MVI + B12 ≥ 100 μg. Clinical outcomes were assessed at 3 years for each group using the Unified Parkinson’s Disease Rating Scale (UPDRS), its subscores, and selected individual questions.
Results Of the 1,147 participants who completed the 3-year visit, 41% took an MVI, 2% took B12, 3% took MVI + B12, and 54% reported taking no supplements. At 3 years, no significant differences in clinical outcomes were observed. However, there was a trend toward lower hazard ratios for developing sensory symptoms (UPDRS Item 17) in the MVI (p = 0.08) and B12 + MVI (p = 0.08) groups compared to that in the no supplement group.
Conclusion These results show that supplementation with vitamin B12 ≥ 100 μg is uncommon in early PD. The finding of a trend toward a lower hazard ratio for the development of sensory symptoms in those taking an MVI or B12 + MVI warrants further study.
Citations
Citations to this article as recorded by
Peripheral neuropathy in Parkinson’s disease: prevalence and functional impact on gait and balance Marta Francisca Corrà, Nuno Vila-Chã, Ana Sardoeira, Clint Hansen, Ana Paula Sousa, Inês Reis, Firmina Sambayeta, Joana Damásio, Margarida Calejo, Andreas Schicketmueller, Inês Laranjinha, Paula Salgado, Ricardo Taipa, Rui Magalhães, Manuel Correia, Walte Brain.2023; 146(1): 225. CrossRef
Could Vitamins Have a Positive Impact on the Treatment of Parkinson’s Disease? Sandeep, Manas Sahu, Linchi Rani, Arun Kharat, Amal Mondal Brain Sciences.2023; 13(2): 272. CrossRef
Long‐Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men Mario H. Flores‐Torres, Chadwick W. Christine, Kjetil Bjornevik, Samantha A. Molsberry, Albert Y. Hung, Brian C. Healy, Deborah Blacker, Michael A. Schwarzschild, Alberto Ascherio Movement Disorders.2023; 38(5): 866. CrossRef
Chaudhuri’s Dashboard of Vitals in Parkinson’s syndrome: an unmet need underpinned by real life clinical tests Mubasher A. Qamar, Silvia Rota, Lucia Batzu, Indu Subramanian, Cristian Falup-Pecurariu, Nataliya Titova, Vinod Metta, Iulia Murasan, Per Odin, Chandrasekhara Padmakumar, Prashanth L. Kukkle, Rupam Borgohain, Rukmini Mridula Kandadai, Vinay Goyal, Kallol Frontiers in Neurology.2023;[Epub] CrossRef
An Investigation into the Effects of Water- and Fat-Soluble Vitamins in Alzheimer's and Parkinson's Diseases Mohammad Shahverdi, Zahra Sourani, Marzieh Sargolzaie, Mostafa Modarres Mousavi, Behnam Bakhtiari moghadam, Sadegh Shirian The Neuroscience Journal of Shefaye Khatam.2023; 11(3): 95. CrossRef
Folic Acid and Vitamin B12 Prevent Deleterious Effects of Rotenone on Object Novelty Recognition Memory and Kynu Expression in an Animal Model of Parkinson’s Disease Gabriela Canalli Kretzschmar, Adriano D. S. Targa, Sheila Coelho Soares-Lima, Priscila Ianzen dos Santos, Lais S. Rodrigues, Daniel A. Macedo, Luis Felipe Ribeiro Pinto, Marcelo M. S. Lima, Angelica Beate Winter Boldt Genes.2022; 13(12): 2397. CrossRef
The Role of Vitamins in Neurodegenerative Disease: An Update Sachchida Nand Rai, Payal Singh, Harry W.M. Steinbusch, Emanuel Vamanu, Ghulam Ashraf, Mohan Prasad Singh Biomedicines.2021; 9(10): 1284. CrossRef
Vitamin B12 measurements across neurodegenerative disorders Nijee S. Luthra, Ariane H. Marcus, Nancy K. Hills, Chadwick W. Christine Journal of Clinical Movement Disorders.2020;[Epub] CrossRef
Lower Vitamin B12 Level at Multiple System Atrophy Diagnosis Is Associated With Shorter Survival Stuart J. McCarter, Elizabeth A. Coon, Rodolfo Savica, Erik K. St Louis, James H. Bower, Eduardo E. Benarroch, Paola Sandroni, Phillip Low, Wolfgang Singer Movement Disorders.2020; 35(8): 1462. CrossRef
Protection from the Pathogenesis of Neurodegenerative Disorders, including Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Huntington’s Disease, and Parkinson’s Diseases, through the Mitigation of Reactive Oxygen Species S* Madireddy, S Madireddy Journal of Neuroscience and Neurological Disorders.2019; 3(2): 148. CrossRef
Objective Directional leads are used for deep brain stimulation (DBS). Two of the four contacts of the leads are divided into three parts, enabling controlled stimulation in a circumferential direction. The direction of adverse effects evoked by DBS in the subthalamic nucleus (STN) and stimulation strategies using directional leads were evaluated. Methods Directional leads were implanted into the bilateral STN of six parkinsonian patients (1 man, 5 women; mean age 66.2 years). The contact centers were located within the upper border of the STN, and the locations were identified electrically using microrecordings. Adverse effects were evaluated with electrical stimulation (30 μs, 130 Hz, limit 11 mA) using the directional part of each lead after surgery, and the final stimulation direction was investigated. Unified Parkinson’s disease rating scale (UPDRS) scores were evaluated before and after DBS. Results Fifty-six motor and four sensory symptoms were evoked by stimulation; no adverse effect was evoked in 14 contacts. Motor and sensory symptoms were evoked by stimulation in the anterolateral direction and medial to posterolateral direction, respectively. Stimulation in the posteromedial direction produced adverse effects less frequently. The most frequently used contacts were located above the STN (63%), followed by the upper part of the STN (32%). The mean UPDRS part III and dyskinesia scores decreased after DBS from 30.2 ± 11.7 to 7.2 ± 2.9 and 3.3 ± 2.4 to 0.5 ± 0.8, respectively. Conclusion The incidence of adverse effects was low for the posteromedial stimulation of the STN. Placing the directional part of the lead above the STN may facilitate the control of dyskinesia.
Citations
Citations to this article as recorded by
Directional deep brain stimulation in the management of Parkinson’s disease: efficacy and constraints—an analytical appraisal Mayara Tszesnioski Maçaneiro, Ana Clara Azevedo, Bruna Maurício Poerner, Milena Dangui da Silva, Andrei Koerbel Neurosurgical Review.2024;[Epub] CrossRef
Globus pallidus internus versus subthalamic nucleus deep brain stimulation for isolated dystonia: A 3‐year follow‐up Suzhen Lin, Yimei Shu, Chencheng Zhang, Lingbing Wang, Peng Huang, Yixin Pan, Jianqing Ding, Bomin Sun, Dianyou Li, Yiwen Wu European Journal of Neurology.2023; 30(9): 2629. CrossRef
Three-dimensional gait analysis of the effect of directional steering on gait in patients with Parkinson's disease Satoko Sekimoto, Genko Oyama, Kotatsu Bito, Masaru Tsuchiya, Sho Kikuchi, Baku Takimoto, Toshiki Ichihashi, Juan Miguel P. Bautista, Maierdanjiang Nuermaimaiti, Fuyuko Sasaki, Ryota Nakamura, Hirokazu Iwamuro, Masanobu Ito, Atsushi Umemura, Nobutaka Hatto Parkinsonism & Related Disorders.2023; 114: 105770. CrossRef
Do directional deep brain stimulation leads rotate after implantation? Marie T. Krüger, Yashar Naseri, Fabian Cavalloni, Peter C. Reinacher, Georg Kägi, Johannes Weber, Deborah Brogle, Oliver Bozinov, Stefan Hägele-Link, Florian Brugger Acta Neurochirurgica.2021; 163(1): 197. CrossRef
Stimulation-Induced Dyskinesia After Subthalamic Nucleus Deep Brain Stimulation in Patients With Meige Syndrome Ning Wang, Kailiang Wang, Qiao Wang, Shiying Fan, Zonghui Fu, Feng Zhang, Lin Wang, Fangang Meng Neuromodulation: Technology at the Neural Interface.2021; 24(2): 286. CrossRef
Deep brain stimulation programming strategies: segmented leads, independent current sources, and future technology Bhavana Patel, Shannon Chiu, Joshua K. Wong, Addie Patterson, Wissam Deeb, Matthew Burns, Pamela Zeilman, Aparna Wagle-Shukla, Leonardo Almeida, Michael S. Okun, Adolfo Ramirez-Zamora Expert Review of Medical Devices.2021; 18(9): 875. CrossRef
Deep-Brain Stimulation for Essential Tremor and Other Tremor Syndromes: A Narrative Review of Current Targets and Clinical Outcomes Christian Iorio-Morin, Anton Fomenko, Suneil K. Kalia Brain Sciences.2020; 10(12): 925. CrossRef
Dyskinesia‐inducing lead contacts optimize outcome of subthalamic stimulation in Parkinson's disease Walid Bouthour, Matthieu Béreau, Astrid Kibleur, André Zacharia, Emilie Tomkova Chaoui, Vanessa Fleury, Damien Benis, Shahan Momjian, Julien Bally, Christian Lüscher, Paul Krack, Pierre R. Burkhard Movement Disorders.2019; 34(11): 1728. CrossRef
Objective It is unclear whether the decline in dopamine transporters (DAT) differs among idiopathic rapid eye movement sleep behavior disorder (iRBD) patients with different levels of olfactory impairment. This study aimed to characterize DAT changes in relation to nonmotor features in iRBD patients by olfactory loss.
Methods This prospective cohort study consisted of three age-matched groups: 30 polysomnography-confirmed iRBD patients, 30 drug-naïve Parkinson’s disease patients, and 19 healthy controls without olfactory impairment. The iRBD group was divided into two groups based on olfactory testing results. Participants were evaluated for reported prodromal markers and then underwent 18F-FP-CIT positron emission tomography and 3T MRI. Tracer uptakes were analyzed in the caudate, anterior and posterior putamen, substantia nigra, and raphe nuclei.
Results Olfactory impairment was defined in 38.5% of iRBD patients. Mild parkinsonian signs and cognitive functions were not different between the two iRBD subgroups; however, additional prodromal features, constipation, and urinary and sexual dysfunctions were found in iRBD patients with olfactory impairment but not in those without. Tracer uptake showed significant group differences in all brain regions, except the raphe nuclei. The iRBD patients with olfactory impairment had uptake reductions in the anterior and posterior putamen, caudate, and substantia nigra (p < 0.016 in all, adjusted for age), which ranged from 0.6 to 0.8 of age-normative values. In contrast, those without olfactory impairment had insignificant changes in all regions ranging above 0.8.
Conclusion There was a clear distinction in DAT loss and nonmotor profiles by olfactory status in iRBD.
Citations
Citations to this article as recorded by
Neuropsychological Changes in Isolated REM Sleep Behavior Disorder: A Systematic Review and Meta-analysis of Cross-sectional and Longitudinal Studies Caterina Leitner, Giada D’Este, Laura Verga, Shady Rahayel, Samantha Mombelli, Marco Sforza, Francesca Casoni, Marco Zucconi, Luigi Ferini-Strambi, Andrea Galbiati Neuropsychology Review.2024; 34(1): 41. CrossRef
Dopamine transporter positron emission tomography in patients with Alzheimer’s disease with Lewy body disease features Sungwoo Kang, Seun Jeon, Young-gun Lee, Byoung Seok Ye Neurobiology of Aging.2024; 134: 57. CrossRef
Imaging Procedure and Clinical Studies of [18F]FP-CIT PET Changhwan Sung, Seung Jun Oh, Jae Seung Kim Nuclear Medicine and Molecular Imaging.2024; 58(4): 185. CrossRef
Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort Beatrice Orso, Pietro Mattioli, Eun-Jin Yoon, Yu Kyeong Kim, Heejung Kim, Jung Hwan Shin, Ryul Kim, Claudio Liguori, Francesco Famà, Andrea Donniaquio, Federico Massa, David Vállez García, Sanne K. Meles, Klaus L. Leenders, Agostino Chiaravalloti, Matteo Neurological Sciences.2023; 44(9): 3161. CrossRef
Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder Don Gueu Park, Ju Yeong Kim, Min Seung Kim, Mi Hee Kim, Young-Sil An, Jaerak Chang, Jung Han Yoon Journal of Neurology.2023; 270(9): 4393. CrossRef
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study Jung Hwan Shin, Heejung Kim, Yu Kyeong Kim, Eun Jin Yoon, Hyunwoo Nam, Beomseok Jeon, Jee-Young Lee Translational Neurodegeneration.2023;[Epub] CrossRef
Brain olfactory‐related atrophy in isolated rapid eye movement sleep behavior disorder Kyung Ah Woo, Heejung Kim, Eun Jin Yoon, Jung Hwan Shin, Hyunwoo Nam, Beomseok Jeon, Yu Kyeong Kim, Jee‐Young Lee Annals of Clinical and Translational Neurology.2023; 10(12): 2192. CrossRef
Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease Kyung Ah Woo, Joo Hong Joun, Eun Jin Yoon, Chan Young Lee, Beomseok Jeon, Yu Kyeong Kim, Jee‐Young Lee Movement Disorders.2023; 38(12): 2291. CrossRef
Altered cerebral perfusion and microstructure in advanced Parkinson’s disease and their associations with clinical features Zhaoxi Liu, Yiwei Zhang, Han Wang, Dan Xu, Hui You, Zhentao Zuo, Feng Feng Neurological Research.2022; 44(1): 47. CrossRef
Brain Neuroimaging of Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease: A Systematic Review Rafail Matzaras, Kuangyu Shi, Artemios Artemiadis, Panagiotis Zis, Georgios Hadjigeorgiou, Axel Rominger, Claudio L.A. Bassetti, Panagiotis Bargiotas Journal of Parkinson's Disease.2022; 12(1): 69. CrossRef
Odor Identification by Parkinson’s Disease Patients Tested by Using Sniffin’ Sticks versus Natural Spices Florence Baert, Geertrui Vlaemynck, Jarissa Maselyne, Christophe Matthys, Seyed-Mohammad Fereshtehnejad Parkinson's Disease.2022; 2022: 1. CrossRef
Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease Ryul Kim, Heejung Kim, Yu Kyeong Kim, Eun Jin Yoon, Hyun Woo Nam, Beomseok Jeon, Jee‐Young Lee Movement Disorders.2022; 37(10): 2099. CrossRef
Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder‐Related Metabolic Pattern Expression Ryul Kim, Jee‐Young Lee, Yu Kyeong Kim, Heejung Kim, Eun Jin Yoon, Jung Hwan Shin, Dallah Yoo, Hyunwoo Nam, Beomseok Jeon Movement Disorders.2021; 36(8): 1889. CrossRef
Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder Jung Hwan Shin, Jee-Young Lee, Yu-Kyeong Kim, Eun Jin Yoon, Heejung Kim, Hyunwoo Nam, Beomseok Jeon Neurology.2021;[Epub] CrossRef
Retina Thickness as a Marker of Neurodegeneration in Prodromal Lewy Body Disease Jee‐Young Lee, Jeeyun Ahn, Sohee Oh, Joo Young Shin, Yu Kyeong Kim, Hyunwoo Nam, Beomseok Jeon Movement Disorders.2020; 35(2): 349. CrossRef
Serum TNF-α and neurodegeneration in isolated REM sleep behavior disorder Ryul Kim, Jee-Young Lee, Han-Joon Kim, Yu Kyeong Kim, Hyunwoo Nam, Beomseok Jeon Parkinsonism & Related Disorders.2020; 81: 1. CrossRef
Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder Jung Hwan Shin, Jee-Young Lee, Yu-Kyeong Kim, Sung-A Shin, Heejung Kim, Hyunwoo Nam, Beomseok Jeon Neurology.2020;[Epub] CrossRef
Objective Ample evidence has suggested that age at onset of Parkinson’s disease (PD) is associated with heterogeneous clinical features in individuals. We hypothesized that this may be attributed to different patterns of nigrostriatal dopamine loss.
Methods A total of 205 consecutive patients with de novo PD who underwent 18F-FP-CIT PET scans (mean follow-up duration, 6.31 years) were divided into three tertile groups according to their age at onset of parkinsonian motor symptoms. Striatal dopamine transporter (DAT) availability was compared between the old- (n = 73) and young-onset (n = 66) groups. In addition, the risk of developing freezing of gait (FOG) and longitudinal requirements for dopaminergic medications were examined.
Results The old-onset PD group (mean age at onset, 72.66 years) exhibited more severe parkinsonian motor signs than the young-onset group (52.58 years), despite comparable DAT availability in the posterior putamen; moreover, the old-onset group exhibited more severely decreased DAT availability in the caudate than the young-onset group. A Cox regression model revealed that the old-onset PD group had a higher risk for developing FOG than the young-onset group [hazard ratio 2.523, 95% confidence interval (1.239–5.140)]. The old-onset group required higher doses of dopaminergic medications for symptom control than the young-onset group over time.
Conclusion The present study demonstrated that the old-onset PD group exhibited more severe dopamine loss in the caudate and were more likely to develop gait freezing, suggesting that age at onset may be one of the major determinants of the pattern of striatal dopamine depletion and progression of gait disturbance in PD.
Citations
Citations to this article as recorded by
The Molecular Pathway of p75 Neurotrophin Receptor (p75NTR) in Parkinson’s Disease: The Way of New Inroads Naif H. Ali, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Saud A. Alnaaim, Hebatallah M. Saad, Gaber El-Saber Batiha Molecular Neurobiology.2024; 61(5): 2469. CrossRef
Patterns of regional cerebral hypoperfusion in early Parkinson's disease: Clinical implications Seok Jong Chung, Su Hong Kim, Chan Wook Park, Hye Sun Lee, Mijin Yun, Yun Joong Kim, Young H. Sohn, Yong Jeong, Phil Hyu Lee Parkinsonism & Related Disorders.2024; 121: 106024. CrossRef
Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue Areej Turkistani, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Athanasios Alexiou, Marios Papadakis, Mohamed M. Elfiky, Hebatallah M. Saad, Gaber El-Saber Batiha Molecular Neurobiology.2024;[Epub] CrossRef
Imaging Procedure and Clinical Studies of [18F]FP-CIT PET Changhwan Sung, Seung Jun Oh, Jae Seung Kim Nuclear Medicine and Molecular Imaging.2024; 58(4): 185. CrossRef
Association of Family History and Polygenic Risk Score With Longitudinal Prognosis in Parkinson Disease Mincheol Park, Young-gun Lee Neurology Genetics.2024;[Epub] CrossRef
Hippocampal Perfusion Affects Motor and Cognitive Functions in Parkinson Disease: An Early Phase 18F‐FP‐CIT Positron Emission Tomography Study Min Young Chun, Seok Jong Chung, Su Hong Kim, Chan Wook Park, Seong Ho Jeong, Hye Sun Lee, Phil Hyu Lee, Young H. Sohn, Yong Jeong, Yun Joong Kim Annals of Neurology.2024; 95(2): 388. CrossRef
The effects of cholesterol and statins on Parkinson’s neuropathology: a narrative review Hayder M. Al-kuraishy, Esraa H. Fahad, Salah Al-Windy, Suzy A. El-Sherbeni, Walaa A. Negm, Gaber El-Saber Batiha Inflammopharmacology.2024; 32(2): 917. CrossRef
BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy Naif H. Ali, Hayder M. Al‐Kuraishy, Ali I. Al‐Gareeb, Athanasios Alexiou, Marios Papadakis, Ali Abdullah AlAseeri, Mubarak Alruwaili, Hebatallah M. Saad, Gaber El‐Saber Batiha Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
Mid- and late-life lifestyle activities as main drivers of general and domain-specific cognitive reserve in individuals with Parkinson’s disease: cross-sectional and longitudinal evidence from the LANDSCAPE study Anja Ophey, Kathrin Wirtz, Steffen Wolfsgruber, Monika Balzer-Geldsetzer, Daniela Berg, Rüdiger Hilker-Roggendorf, Jan Kassubek, Inga Liepelt-Scarfone, Sara Becker, Britt Mollenhauer, Kathrin Reetz, Oliver Riedel, Jörg B. Schulz, Alexander Storch, Claudia Journal of Neurology.2024; 271(8): 5411. CrossRef
The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles? Merle C. Hoenig, Verena Dzialas, Alexander Drzezga, Thilo van Eimeren Movement Disorders.2023; 38(1): 16. CrossRef
Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment Mattia Siciliano, Rosa De Micco, Andrea Gerardo Russo, Fabrizio Esposito, Valeria Sant'Elia, Lucia Ricciardi, Francesca Morgante, Antonio Russo, Jennifer G. Goldman, Carlo Chiorri, Gioacchino Tedeschi, Luigi Trojano, Alessandro Tessitore Movement Disorders.2023; 38(8): 1461. CrossRef
A meta-analysis identifies factors predicting the future development of freezing of gait in Parkinson’s disease Talia Herman, Yael Barer, Michal Bitan, Shani Sobol, Nir Giladi, Jeffrey M. Hausdorff npj Parkinson's Disease.2023;[Epub] CrossRef
Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson’s Disease Seong Ho Jeong, Seok Jong Chung, Han Soo Yoo, Jin Ho Jung, Kyoungwon Baik, Yang Hyun Lee, Phil Hyu Lee, Young H. Sohn Journal of Parkinson's Disease.2022; 12(1): 129. CrossRef
Treatment Enhances Betweenness Centrality of Fronto-Parietal Network in Parkinson’s Patients Qing Liu, ZhongYan Shi, Kexin Wang, Tiantian Liu, Shintaro Funahashi, Jinglong Wu, Jian Zhang Frontiers in Computational Neuroscience.2022;[Epub] CrossRef
Identifying the white matter structural network of motor reserve in early Parkinson's disease Yae Ji Kim, Chan Wook Park, Hye Won Shin, Hye Sun Lee, Yun Joong Kim, Mijin Yun, Phil Hyu Lee, Young H. Sohn, Yong Jeong, Seok Jong Chung Parkinsonism & Related Disorders.2022; 102: 108. CrossRef
Potential Link Between Cognition and Motor Reserve in Patients With Parkinson’s Disease Seok Jong Chung, Yae Ji Kim, Yun Joong Kim, Hye Sun Lee, Mijin Yun, Phil Hyu Lee, Yong Jeong, Young H. Sohn Journal of Movement Disorders.2022; 15(3): 249. CrossRef
Association Between White Matter Networks and the Pattern of Striatal Dopamine Depletion in Patients With Parkinson Disease Seok Jong Chung, Yae Ji Kim, Yun Joong Kim, Hye Sun Lee, Seong Ho Jeong, Ji-Man Hong, Young H. Sohn, Mijin Yun, Yong Jeong, Phil Hyu Lee Neurology.2022;[Epub] CrossRef
Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease Seok Jong Chung, John Hoon Rim, Dajeong Ji, Sangwon Lee, Han Soo Yoo, Jin Ho Jung, KyoungWon Baik, Yonghoon Choi, Byoung Seok Ye, Young H. Sohn, Mijin Yun, Sang-Guk Lee, Phil Hyu Lee Nutrition.2021; 83: 111090. CrossRef
White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease Seong Ho Jeong, Hye Sun Lee, Jin Ho Jung, Kyoungwon Baik, Yang Hyun Lee, Han Soo Yoo, Young H. Sohn, Seok Jong Chung, Phil Hyu Lee Movement Disorders.2021; 36(6): 1411. CrossRef
Temporalis Muscle Thickness as an Indicator of Sarcopenia Is Associated With Long-term Motor Outcomes in Parkinson’s Disease Seok Jong Chung, Yun Joong Kim, Han Soo Yoo, Jin Ho Jung, KyoungWon Baik, Hye Sun Lee, Yang Hyun Lee, Ji-Man Hong, Young H Sohn, Phil Hyu Lee, Jay Magaziner The Journals of Gerontology: Series A.2021; 76(12): 2242. CrossRef
Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnosed Parkinson Disease Seok Jong Chung, Han Soo Yoo, Na-Young Shin, Yae Won Park, Hye Sun Lee, Ji-Man Hong, Yun Joong Kim, Seung-Koo Lee, Phil Hyu Lee, Young H. Sohn Neurology.2021;[Epub] CrossRef
Diagnosis and treatment of old-onset Parkinson's disease 久大 立花 Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics.2021; 58(3): 341. CrossRef
Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease Myung Jun Lee, Kyoungjune Pak, Han-Kyeol Kim, Kelly N. Nudelman, Jong Hun Kim, Yun Hak Kim, Junho Kang, Min Seok Baek, Chul Hyoung Lyoo npj Parkinson's Disease.2021;[Epub] CrossRef
Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single‐Photon Emission Computed Tomography Study Giovanni Palermo, Sara Giannoni, Daniela Frosini, Riccardo Morganti, Duccio Volterrani, Ubaldo Bonuccelli, Nicola Pavese, Roberto Ceravolo Movement Disorders.2020; 35(6): 1028. CrossRef
Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and 11C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease Xiaohong Li, Qizhou Zhang, Yongde Qin, Yubin Li, Nazimuguli Mutaerbieke, Xiaojia Zhao, Amina Yibulayin Medicine.2020; 99(14): e19662. CrossRef
DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study Christos Koros, Athina-Maria Simitsi, Andreas Prentakis, Nikolaos Papagiannakis, Anastasia Bougea, Ioanna Pachi, Dimitra Papadimitriou, Ion Beratis, Sokratis G. Papageorgiou, Maria Stamelou, Xenia Geronicola Trapali, Leonidas Stefanis Parkinsonism & Related Disorders.2020; 77: 36. CrossRef
Prediction of age at onset in Parkinson’s disease using objective specific neuroimaging genetics based on a sparse canonical correlation analysis Ji Hye Won, Mansu Kim, Jinyoung Youn, Hyunjin Park Scientific Reports.2020;[Epub] CrossRef
Emerging Concepts of Motor Reserve in Parkinson’s Disease Seok Jong Chung, Jae Jung Lee, Phil Hyu Lee, Young H. Sohn Journal of Movement Disorders.2020; 13(3): 171. CrossRef
Jong Hyeon Ahn, Ah Reum Kim, Nayoung K. D. Kim, Woong-Yang Park, Ji Sun Kim, Minkyeong Kim, Jongkyu Park, Jung-Il Lee, Jin Whan Cho, Kyung Rae Cho, Jinyoung Youn
J Mov Disord. 2019;12(2):120-124. Published online May 30, 2019
Objective The aim of this study was to investigate the efficacy of globus pallidus interna deep brain stimulation (GPi-DBS) for treating dystonia due to the GNAL mutation.
Methods We provide the first report of a dystonia patient with a genetically confirmed GNAL mutation in the Korean population and reviewed the literature on patients with the GNAL mutation who underwent GPi-DBS. We compared the effectiveness of DBS in patients with the GNAL mutation compared to that in patients with DYT1 and DYT6 in a previous study.
Results Patients with the GNAL mutation and those with DYT1 had higher early responder rates (GNAL, 5/5, 100%; DYT1, 7/7, 100%) than did patients with DYT6 (p = 0.047). The responder rates at late follow-up did not differ statistically among the three groups (p = 0.278). The decrease in the dystonia motor scale score in the GNAL group was 46.9% at early follow-up and 63.4% at late follow-up.
Conclusion GPi-DBS would be an effective treatment option for dystonia patients with the GNAL mutation who are resistant to medication or botulinum toxin treatment.
Citations
Citations to this article as recorded by
The role of genetics in the treatment of dystonia with deep brain stimulation: Systematic review and Meta-analysis Harini Sarva, Federico Rodriguez-Porcel, Francisco Rivera, Claudio Daniel Gonzalez, Samantha Barkan, Susmit Tripathi, Emilia Gatto, Pedro Garcia Ruiz Journal of the Neurological Sciences.2024; 459: 122970. CrossRef
Pediatric Onset of Generalized Dystonia, Cognitive Impairment, and Dysmorphic Features in a Patient Carrying Compound Heterozygous GNAL Mutations Luca Magistrelli, Elena Contaldi, Beatrice Piola, Fjorilda Caushi, Miryam Carecchio, Sandra D'Alfonso, Lucia Corrado Movement Disorders Clinical Practice.2024; 11(8): 1047. CrossRef
BDNF-Regulated Modulation of Striatal Circuits and Implications for Parkinson’s Disease and Dystonia Daniel Wolf, Maurilyn Ayon-Olivas, Michael Sendtner Biomedicines.2024; 12(8): 1761. CrossRef
A novel GNAL pathogenic variant leading to generalized dystonia: Immediate and sustained response to globus pallidus internus deep brain stimulation Luigi Michele Romito, Fabio Paio, Nico Golfrè Andreasi, Celeste Panteghini, Sara Rinaldo, Ahmet Kaymak, Alberto Mazzoni, Fabiana Colucci, Vincenzo Levi, Giuseppe Messina, Barbara Garavaglia, Roberto Eleopra Parkinsonism & Related Disorders.2023; 115: 105833. CrossRef
Applicability of clinical genetic testing for deep brain stimulation treatment in monogenic Parkinson’s disease and monogenic dystonia: a multidisciplinary team perspective Valentino Rački, Mario Hero, Eliša Papić, Gloria Rožmarić, Nada Starčević Čizmarević, Darko Chudy, Borut Peterlin, Vladimira Vuletić Frontiers in Neuroscience.2023;[Epub] CrossRef
Isolated dystonia: clinical and genetic updates Aloysius Domingo, Rachita Yadav, Laurie J. Ozelius Journal of Neural Transmission.2021; 128(4): 405. CrossRef
Abnormal cerebellar function and tremor in a mouse model for non‐manifesting partially penetrant dystonia type 6 Meike E. van der Heijden, Dominic J. Kizek, Ross Perez, Elena K. Ruff, Michelle E. Ehrlich, Roy V. Sillitoe The Journal of Physiology.2021; 599(7): 2037. CrossRef
Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome Stephen Tisch, Kishore Raj Kumar Frontiers in Neurology.2021;[Epub] CrossRef
Arching deep brain stimulation in dystonia types Han-Joon Kim, Beomseok Jeon Journal of Neural Transmission.2021; 128(4): 539. CrossRef
The Efficacy and Predictors of Using GPi-DBS to Treat Early-Onset Dystonia: An Individual Patient Analysis Wenxiu Chen, Houyou Fan, Guohui Lu, Fushun Wang Neural Plasticity.2021; 2021: 1. CrossRef
Deep brain stimulation in dystonia: State of art and future directions A. Macerollo, V. Sajin, M. Bonello, D. Barghava, S. H Alusi, P. R Eldridge, J. Osman-Farah Journal of Neuroscience Methods.2020; 340: 108750. CrossRef
Successful Pallidal Stimulation in a Patient with KMT2B-Related Dystonia Jun Kyu Mun, Ah Reum Kim, Jong Hyeon Ahn, Minkyeong Kim, Jin Whan Cho, Jung-Il Lee, Kyung Rae Cho, Jinyoung Youn Journal of Movement Disorders.2020; 13(2): 154. CrossRef
Clinical characteristics of ataxia-telangiectasia presenting dystonia as a main manifestation Minkyeong Kim, Ah Reum Kim, Jongkyu Park, Ji Sun Kim, Jong Hyeon Ahn, Woong-Yang Park, Nayoung K.D. Kim, Chung Lee, Nam-Soon Kim, Jin Whan Cho, Jinyoung Youn Clinical Neurology and Neurosurgery.2020; 199: 106267. CrossRef
Reply to: The Spectrum of Movement Disorders in 18p Deletion Syndrome David Crosiers, Bettina Blaumeiser, Gert Van Goethem Movement Disorders Clinical Practice.2019; 6(8): 731. CrossRef
Task-specific oromandibular dystonia secondary to chewing Khat (Catha edulis)- A series of 35 cases Pettarusp Murzban Wadia, Vaibhav Mathur, Prashanth Lingappa Kukkle, Jitendra N. Khanna Parkinsonism & Related Disorders.2023; 114: 105806. CrossRef
Function and dysfunction of the dystonia network: an exploration of neural circuits that underlie the acquired and isolated dystonias Jason S. Gill, Megan X. Nguyen, Mariam Hull, Meike E. van der Heijden, Ken Nguyen, Sruthi P. Thomas, Roy V. Sillitoe Dystonia.2023;[Epub] CrossRef
Isolated speech-induced lingual dystonia successfully treated with botulinum neurotoxin C. Cores-Bartolomé, J.M. Paz-González, M.J. García-Antelo, D. Santos-García Neurología.2022; 37(4): 306. CrossRef
Isolated speech-induced lingual dystonia successfully treated with botulinum neurotoxin C. Cores-Bartolomé, J.M. Paz-González, M.J. García-Antelo, D. Santos-García Neurología (English Edition).2022; 37(4): 306. CrossRef
Unraveling belly dancer’s dyskinesia and other puzzling diagnostic contortions: A narrative literature review Jamir Pitton Rissardo, Nilofar Murtaza Vora, Irra Tariq, Vanshika Batra, Ana Letícia Fornari Caprara Brain Circulation.2024; 10(2): 106. CrossRef
A Rare Case Report: Belly Dancer Dyskinesia and Symptomatic Epilepsy in Pregnancy Causing Incomplete Uterine Rupture Peby M Lestari, Hana Andrina, Arpian Herponi Journal of South Asian Federation of Obstetrics and Gynaecology.2024; 16(4): 455. CrossRef
A case report and a brief literature review of belly dancer’s dyskinesia in a pregnant patient Abenet Tafesse Mengesha, Surafel Tilahun Maru, Mohammadjavad Ashrafi Mahabadi, Matyas Adugna Abebe, Berhanu Moges Abera, Ehsan Derafsh SAGE Open Medical Case Reports.2023; 11: 2050313X2311777. CrossRef
Belly dancer's dyskinesia during pregnancy: A rare case from South Korea Yeonseong Jeong, Min‐A Kim International Journal of Gynecology & Obstetrics.2023; 163(1): 328. CrossRef
Belly Dancer Dyskinesia During Pregnancy: Case Report from Harar, Eastern Ethiopia Tadesse Gure International Medical Case Reports Journal.2021; Volume 14: 839. CrossRef
Striking Alleviation of down the Stairs Dystonia by Ankle Tightening Shiro Horisawa, Takakazu Kawamata, Takaomi Taira Movement Disorders Clinical Practice.2023; 10(2): 341. CrossRef
An unusual cause of difficulty in walking downstairs: Focal task‐specific dystonia in the lower limb Takafumi Hasegawa Clinical Case Reports.2020; 8(8): 1595. CrossRef
Focal Task-Specific Lower Limb Dystonia Only When Walking Stairs: Is It a New Disease Entity? Jong Sam Baik, Hyeo-Il Ma, Phil Hyu Lee, Takaomi Taira Frontiers in Neurology.2019;[Epub] CrossRef
White matter and cerebellar involvement in alternating hemiplegia of childhood Mariasavina Severino, Livia Pisciotta, Domenico Tortora, Benedetta Toselli, Michela Stagnaro, Ramona Cordani, Giovanni Morana, Anna Zicca, Svetlana Kotzeva, Clelia Zanaboni, Giovanni Montobbio, Andrea Rossi, Elisa De Grandis Journal of Neurology.2020; 267(5): 1300. CrossRef
Copper, Iron, and Manganese Toxicity in Neuropsychiatric Conditions Beata Tarnacka, Anna Jopowicz, Maria Maślińska International Journal of Molecular Sciences.2021; 22(15): 7820. CrossRef